Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

610 results about "Acid derivative" patented technology

Fibric acid derivatives or fibrates are regarded as broad-spectrum lipid lowering drugs. Their main action is to decrease triglyceride levels but they also tend to reduce low density lipoprotein (LDL) cholesterol levels and help to raise high density lipoprotein (HDL) cholesterol.

Method for improving health condition of mammal or farm animal

A method for improving health conditions of mammals or livestock by feeding, to the mammals or livestock, a licorice extract including: (A) glycyrrhizic acid, a glycyrrhizic acid derivative, glycyrrhetinic acid, and / or a glycyrrhetinic acid derivative; (B) licorice saponins other than (A); and (C) licorice flavonoids; (B) including at least a licorice saponin H2, a licorice saponin G2, and macedonoside A, (C) including at least liquiritin apioside, isoliquiritin apioside, and isoliquiritin, where feeding is of 0.017 g / day / head or more of the licorice saponin H2, 0.002 g / day / head or more of the licorice saponin G2, and 0.002 g / day / head or more of the macedonoside A, 0.001 g / day / head or more of the liquiritin apioside, 0.001 g / day / head or more of the isoliquiritin apioside, and 0.001 g / day / head or more of the isoliquiritin.
Owner:ONISHI TAKAO

The invention relates to 2apos; -fluoro-2apos,-fluoro-2apos; -deoxynucleoside-5apos,-deoxynucleoside-5apos; enzymatic synthesis method and application of-triphosphoric acid

The invention discloses a synthetic method of 2 '-fluoro-2'-deoxynucleosid-5 '-triphosphoric acid and application of the 2'-fluoro-2 '-deoxynucleosid-5'-triphosphoric acid. The synthesis method comprises the following steps: reacting in a system containing adenosine triphosphate, 2 '-fluoro-2'-deoxynucleoside, metal ions and deoxynucleoside kinase to obtain 2 '-fluoro-2'-deoxynucleoside-5 '-phosphoric acid; and reacting in a system containing polyphosphoric acid, 2 '-fluoro-2'-deoxynucleoside-5 '-phosphoric acid, metal ions and polyphosphate kinase to obtain 2'-fluoro-2 '-deoxynucleoside-5'-triphosphoric acid. The obtained 2 '-fluoro-2'-deoxynucleoside-5 '-triphosphoric acid can be used for preparing heterologous nucleic acid. The invention provides an economic and green new way for synthesis of 2 '-fluoro-2'-deoxynucleoside-5 '-triphosphate, solves the problems of complex steps, non-environment-friendly reagents and high cost in the existing chemical synthesis method, and provides a thought for preparation of nucleotide derivatives.
Owner:SOUTH CHINA UNIV OF TECH

Preparation method of 2-phenylindole derivatives and application thereof

The present invention discloses a preparation method and application of 2-phenylindole derivatives. Palladium acetate and copper acetate are added into a glacial acetic acid solution of an indole derivative (formula I) and an arylphenylboronic acid derivative (formula II), stirred at room temperature, and purified to obtain a 2-phenylindole derivative (formula III). The present invention provides a method for direct one-step synthesis of 2-arylindole compounds from indole derivatives and arylphenylboronic acid derivatives as raw materials. The present invention replaces oxygen with air to participate in an oxidation system, expands substituents of indole ring R1, adds substitution of 5-bit, 6-bit and 7-bit electron withdrawing groups and electron donating groups, further expands the range of substrates, and increases the yield of substitution on indole ring R1 by about 13%, wherein 2-methyl and 3-methoxy substituted by R2 and 6-chlorine substituted by R1 have good antifungal activity.
Owner:SHIHEZI UNIVERSITY

Method for producing 4-ketobenzamide derivative and 4-ketobenzoic acid derivative

To provide a method for producing 4-ketobenzamide derivatives and 4-ketobenzoic acid derivatives.SOLUTION: The present invention provides a method for producing a 4-ketobenzamide compound represented by formula (2), by amidating a compound represented by formula (1), which is obtained through cyanation of a compound represented by formula (3), as well as a method for producing a 4-ketobenzoic acid derivative represented by formula (6), by hydrolyzing the compound represented by formula (1) or the compound represented by formula (2), and a method for producing a 4-ketobenzoic acid ester derivative represented by formula (5), by esterifying the compound represented by formula (2), wherein R1 represents a C1-C6 alkyl group or the like, R2 represents a C1-C6 alkyl group or the like, R3 represents a C1-C6 alkyl group or the like, X represents a halogen atom or the like, Y represents a C1-C6 alkyl group or the like, and n represents an integer of 0-3.SELECTED DRAWING: None
Owner:NISSAN CHEM CORP

Bio-based MS resin and preparation method thereof

PendingCN120441744APolymer scienceCaffeic acid
The invention belongs to the technical field of polymer synthetic materials, and particularly relates to bio-based MS resin and a preparation method thereof. The bio-based MS resin is a free radical copolymer of a methyl methacrylate monomer and a styrene monomer; the methyl methacrylate monomers comprise bio-based methyl methacrylate, isobornyl methacrylate and 3-pinane methacrylate, and the methyl methacrylate monomers comprise methyl methacrylate, isobornyl methacrylate and 3-pinane methacrylate; the styrene monomers comprise styrene and caffeic acid derivatives; based on 100% of the mass of the bio-based MS resin, the methacrylate monomer accounts for 30%; the molar ratio of caffeic acid derivatives to styrene in the styrene monomers is 1: (1-9). The synthesized bio-based MS resin has the characteristics of greenness and reproducibility, compared with petroleum-based MS resin, the performance of the MS resin can be regulated and controlled by designing a protecting group of a bio-based caffeic acid derivative so as to expand the application range of the MS resin, a specific functional group can be introduced to prepare a functional, advanced and high-performance polymer material, and the MS resin has a good market prospect.
Owner:DALIAN UNIV OF TECH

Oil-control acne-removal synergistic composition, sustained-release body, and preparation method and application of oil-control acne-removal synergistic composition and sustained-release body

The invention discloses an oil-controlling and acne-removing synergistic composition which comprises the following components in percentage by weight: 0.8 to 2.0 percent of succinic acid, 0.3 to 1.0 percent of salicylic acid derivative and 0.5 to 1.5 percent of PCA (Principal Component Analysis) zinc. The invention also provides a sustained-release body. The sustained-release body is prepared from the following components in percentage by weight: 0.8 to 2.0 percent of succinic acid, 0.3 to 1.0 percent of salicylic acid derivative, 0.5 to 1.5 percent of PCA zinc, 1.0 to 2.5 percent of lactobionic acid, 1.0 to 3.0 percent of lactobacillus fermentation product, 2.0 to 4.0 percent of aminated modified diatomite and 0.1 to 0.3 percent of citric acid. The invention also provides a preparation method and application of the sustained release body. The acne-removing shampoo has low irritation, and can be used for controlling oil and removing acnes for a long time and efficiently dredging hair follicles.
Owner:GUANGDONG PINSHENG BIOTECHNOLOGY CO LTD

Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element

Provided are: a liquid crystal aligning agent which contains two or more polyamic acids and in which deterioration in liquid crystal aligning properties when stored at room temperature is suppressed; a liquid crystal alignment film obtained from the liquid crystal aligning agent; and a liquid crystal display element. The liquid crystal aligning agent is characterized by containing the following polymer (A) and polymer (B). Polymer (A): a polyamic acid (A) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid containing, as the structural unit derived from the tetracarboxylic acid derivative, a structural unit (a-1Ta) represented by formula (1Ta), and containing, as the structural unit derived from the diamine, a structural unit (a-1Da) represented by formula (1Da), at least a part of the terminal of the polyamic acid (A) contains a non-amino group, the non-amino group is a functional group represented by structural formula (E), and the presence rate of the terminal amino group in the polyamic acid (A) is 60% or less based on the total terminal of the polyamic acid (A). Polymer (B): a polyamic acid (B) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid including a structural unit (b-1Tb) represented by formula (1Tb) as the structural unit derived from the tetracarboxylic acid derivative, and including a structural unit (b-1Db) represented by formula (1Db) as the structural unit derived from the diamine. (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification)
Owner:NISSAN CHEM CORP

Hyaluronic acid derivative pharmaceutical composition and method for producing pharmaceutical composition

A hyaluronic acid derivative pharmaceutical composition comprising (A) a hyaluronic acid derivative into which a hydrophobic group is introduced, (B) an association promoter, and (C) an active ingredient. Preferably, the association accelerator (B) contains at least four ether structures (R-O-R), and satisfies the condition that the number of carbon atoms is 4 or more.
Owner:ASAHI KASEI KOGYO KABUSHIKI KAISHA

A compound mosquito larvae killing composition and its application

The invention discloses a compound mosquito larvae killing composition and application thereof. The compound mosquito larvae killing composition comprises 1% to 5% of active ingredients, 0% to 5% of liquid original drug adsorbent, and 2% to 8% of slow-release coating agent (including 1% to 4% of active ingredients A and active ingredients B, wherein the active ingredient A is a piperic acid derivative compound, and the active ingredient B is selected from any one of pyriproxyfen, fenthion, dimethoate, fenoxycarb, S-methoprene, dinotefuran, thiamethoxam, acetamiprid, imidacloprid, nitenpyram, cyantraniliprole, and chlorantraniliprole. The active ingredients A and B are compounded and processed into granules for mosquito larvae control, and the granules have good lethal effect, long lasting effect, slow-release effect, and reduced labor cost; the compound mosquito larvae killing composition can be widely used in sewage ditches, sewers, and other places, and has special effects on mosquito larvae control.
Owner:JIANGSU YANGNONG CHEM CO LTD

Degradable high-strength medical adhesive as well as preparation method and application thereof

The invention relates to a degradable high-strength medical adhesive and a preparation method and application thereof.The medical adhesive is prepared from raw materials through reaction, the raw materials comprise a component A, a component B and a component C. The component A is trihydric alcohol and derivatives thereof and / or trihydric alcohol modified by polyethylene glycol carboxylic acid derivatives and derivatives thereof, and the component C is trihydric alcohol modified by polyethylene glycol carboxylic acid derivatives and derivatives thereof. The component B is isocyanate, amino acid or an amino acid derivative, and the component C is N-methyldiethanolamine and / or bis (2-ethoxyl)-N-methyl-N-trifluoromethyl ammonium iodide and a derivative of the bis (2-ethoxyl)-N-methyl-N-trifluoromethyl ammonium iodide; the molar ratio of-NCO groups in the component B to total-OH groups in the component A and the component C is 2: 1, and the molar ratio of the component A to the component C is (1-9): 2. The component A and the component C are mixed, heated and dissolved, then a catalyst and the component B are added, and a mixed reaction system is obtained; and cooling after the reaction is completed, adding a rheology modifier, a foaming catalyst and a stabilizer, and uniformly mixing to obtain the degradable high-strength medical adhesive which can be applied to a functional composite material.
Owner:NUOYIMEIER (SHANDONG) MEDICAL TECH CO LTD +1

Preserving solution for stably preserving sample DNA (deoxyribonucleic acid) at normal temperature and preparation method of preserving solution

The invention discloses a preserving fluid for stably preserving sample DNA at normal temperature and a preparation method thereof, and belongs to the technical field of biological sample preservation. The preserving fluid comprises a lysis system, a nucleic acid protection system and a buffering and stabilizing system, the cracking system comprises a composite surfactant and an enzymolysis auxiliary agent; the composite surface active agent is prepared from polyether polyol fatty acid ester and cocamidopropyl hydroxy sulfobetaine; the enzymolysis auxiliary agent comprises lysozyme Lyso-V and protease K; the nucleic acid protection system comprises a nitrogen heterocyclic polyamine-carboxylic acid derivative and dextran sulfate; the nitrogen heterocyclic polyamine-carboxylic acid derivative comprises 1, 4, 7, 10-tetraazacyclododecane-N, N ', N' ', N ''tetraacetic acid, 1, 4, 7-triazacyclononane-N, N', N''-triacetic acid, disodium ethylene diamine tetraacetate-nitrogen heterocyclic derivative, and diethylenetriamine pentaacetic acid-piperazine derivative, and the nitrogen heterocyclic polyamine-carboxylic acid derivative comprises 1, 4, 7, 10-tetraazacyclododecane-N, N ', N '', N'' tetraacetic acid, 1, 4, 7-triazacyclononane-N, N', N ''-triacetic acid. The buffering and stabilizing system comprises an amphoteric buffering agent and a polymer stabilizer; the amphoteric buffering agent comprises 2-(N-morpholino) ethanesulfonic acid and N-tri (hydroxymethyl) methylglycine.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL +1

Amino acid derivative polymeric membrane material and preparation method thereof

The invention relates to the field of membrane material preparation, in particular to an amino acid derivative polymer membrane material and a preparation method thereof. The preparation method provided by the invention comprises the following steps: S1, preparing a polymer solution; S2, forming and depositing a membrane; S3, carrying out surface modification on the membrane; and S4, carrying out crosslinking treatment. The functional polymer membrane material is synthesized through the amino acid derivative, selective separation of specific ions or molecules can be achieved, and good biocompatibility, stability and application prospects are achieved. The technology can be widely applied to multiple fields of biological separation, environment purification, drug delivery and the like, and has remarkable innovativeness and practical value.
Owner:JIANGSU CHUANGTUO NEW MATERIALS CO LTD

Method for synthesizing 2-amino-3-hydroxy-4-oxobutyric acid derivative through enzyme catalysis

According to the method for synthesizing the 2-amino-3-hydroxy-4-oxobutyric acid derivative through enzyme catalysis, threonine aldolase LTA and / or threonine transaldolase LTTA are / is adopted for catalysis, and the 2-amino-3-hydroxy-4-oxobutyric acid derivative with double chiral centers can be efficiently and selectively synthesized.
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES

Starch-indole acid derivatives and their use

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.
Owner:SHANDONG SHANWEI IMMUNOTECH CO LTD

Acridine sulfonamide carboxylic acid derivative as well as preparation method and application thereof

The invention relates to an acridine sulfonamide carboxylic acid derivative as well as a preparation method and application thereof, and the preparation method comprises the following steps: in an alkaline environment, acridine sulfonamide and amino acid or an amino acid derivative are subjected to amidation reaction in an organic solvent, and the acridine sulfonamide carboxylic acid derivative is obtained after purification; wherein the acridine sulfonamide carboxylic acid derivative has two acridine sulfonamide-like groups, and the two acridine sulfonamide-like groups are connected through the amino acid or the amino acid derivative. The yield of the preparation method exceeds 70%, and the luminous efficiency of the prepared acridine sulfonamide carboxylic acid derivative is higher and is about two times that of acridine sulfonamide NSP-SA-NHS.
Owner:YINGKE XINCHUANG (SUZHOU) BIOTECHNOLOGY CO LTD

Royal jelly acid derivative as well as synthesis method, pharmaceutical composition and application thereof

The invention belongs to the technical field of biological medicines, and particularly relates to a royal jelly acid derivative and a synthesis method, a pharmaceutical composition and application thereof. The royal jelly acid derivative is a compound shown as a formula (I), or an enantiomer, a diastereoisomer and a tautomer thereof, or a solvate or a pharmaceutically acceptable salt thereof. A series of royal jelly acid derivatives with novel structures are constructed by using a natural component royal jelly acid derived from royal jelly as an initial raw material, the royal jelly acid derivatives can play a role in resisting pulmonary fibrosis by inhibiting the activity of fibroblasts, the effect of the royal jelly acid derivatives is equivalent to that of pirfenidone, and the royal jelly acid derivatives are expected to be developed into candidate drugs for resisting pulmonary fibrosis. The ceramide NP has excellent effects in anti-inflammatory, anti-allergic and itching-relieving aspects, has a better effect than known ceramide NP, and can be used for preparing health care products, cosmetics and medicines. And # imgabs0 #.
Owner:SHENZHEN DIKEMAN BIOTECHNOLOGY CO LTD

Method for preparing polysubstituted allene carboxylic acid methyl ester compound based on CO2 and photocatalysis

The invention belongs to the technical field of catalytic methods and catalysts, and particularly relates to a method for preparing a polysubstituted allene carboxylic acid methyl ester compound based on CO2 and photocatalysis, which is based on a photocatalytic reaction system, takes CO2 as a carboxyl source, and is prepared through a 1, 3-enyne 1, 3-polysubstituted allene carboxylic acid methyl ester compound under the mild conditions of no photocatalyst and metal, so that the polysubstituted allene carboxylic acid methyl ester compound is obtained. According to the present invention, the efficient synthesis of the polysubstituted allene carboxylic acid derivative is achieved through the 1, 4-alkane carboxylation reaction, the method has advantages of good yield, wide substrate universality, suitableness for the reaction of a variety of functional groups, non-toxicity of the used reagent, and wide application prospect.
Owner:LANZHOU UNIV

Spirocyclopropane tetronic acid derivative, corresponding agricultural composition and application

The invention relates to a novel spirocyclopropane tetronic acid derivative with insecticidal and acaricidal activity as well as preparation and application of the novel spirocyclopropane tetronic acid derivative. Specifically, the invention provides a compound as shown in a formula (I), and an optical isomer, a cis-trans isomer or a pharmaceutically acceptable salt thereof. The compound disclosed by the invention has obvious insecticidal and acaricidal activity, and can be used for developing novel crop insecticidal and acaricidal agents which are low in toxicity, efficient and environment-friendly. # imgabs0 #
Owner:EAST CHINA UNIV OF SCI & TECH

Preparation and application of desoxyribonucleic acid and desoxyribonucleic acid derivative transdermal delivery system

The invention relates to preparation and application of a desoxyribonucleic acid and desoxyribonucleic acid derivative transdermal delivery system, and belongs to the technical field of biological medicine and skin care products. Desoxyribonucleic acid and derivatives thereof have the effects of resisting aging, repairing and the like, but are difficult to penetrate through a skin barrier due to large molecular weight and strong polarity. According to the invention, hydroxyethyl chitosan, desoxyribonucleic acid and derivatives thereof are combined through electrostatic interaction to form the nano-composite. The compound is small in particle size and can promote transdermal absorption through hair follicle or cuticle gaps. The preparation method is simple, does not need an auxiliary reagent, and comprises the step of mixing a hydroxyethyl chitosan solution and a deoxyribonucleic acid derivative solution. Experiments show that the compound significantly enhances the transdermal efficiency, and has the effects of promoting cell repair and proliferation and resisting inflammation. The composition can be used for skin care products, and is high in safety and wide in application prospect.
Owner:ZHONGKE HOUPU (GUANGZHOU) TECH DEV CO LTD

Pyrazole carboxylic acid derivative and pharmaceutical use thereof

A pyrazole carboxylic acid derivative and the pharmaceutical use thereof, in particular, a compound represented by formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, and the use thereof in the preparation of a drug for treating sGC-related diseases.
Owner:HAISCO PHARMACEUTICAL GROUP CO LTD

Systems and methods for producing alkali hydroxides and sulfuric acid or hydrochloric acid

PCT designated stage expiredWO2025043157A1Carbon compoundsHydrocarbon by hydrogenationSulfideCarbonate
In some embodiments the application pertains to processes comprising reacting a component comprising an alkaline earth weak acid with a component comprising an acid to form a component comprising an alkaline earth acid anion and a component comprising a weak acid derivative. At least a portion of the component comprising the alkaline earth acid anion is reacted with a component comprising an alkali sulfate to form a component comprising alkaline earth sulfate and a component comprising an alkali acid anion. At least a portion of the component comprising alkaline earth sulfate is decomposed to form a component comprising alkaline earth oxide, or alkaline earth hydroxide, or alkaline earth carbonate, or alkaline earth sulfide, or a derivative thereof, or any combination thereof, and a component comprising sulfur dioxide, or oxygen, or sulfur trioxide, or a derivative thereof, or any combination thereof.
Owner:INNOVATOR ENERGY LLC

Pharmaceutical application and pharmaceutical composition of 3-phenylglutaric acid derivative

The invention discloses a pharmaceutical application of a 3-phenylglutaric acid derivative and a pharmaceutical composition. The 3-phenylglutaric acid derivative can be used for preparing an FASN inhibition drug. The 3-phenylglutaric acid derivative micromolecule 84-B10 can inhibit FASN in a targeted manner, is used for inhibiting the activity of the FASN, promoting the degradation of the FASN and relieving weight gain, liver fat accumulation, insulin sensitivity decline and glucose tolerance impairment caused by high calorie intake, and can be used for preparing medicines for preventing and treating metabolism-related fatty liver diseases.
Owner:THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV

Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element

Provided are: a liquid crystal aligning agent which contains two or more types of polyamic acids and which suppresses variations in the pretilt angle of a liquid crystal aligning film when stored at room temperature; a liquid crystal aligning film obtained from the liquid crystal aligning agent; and a liquid crystal display element. The liquid crystal aligning agent is characterized in that the liquid crystal aligning agent can form a liquid crystal alignment film with a pretilt angle of more than 0 degree and less than 3 degrees, and the liquid crystal aligning agent contains the following polymer (A) and polymer (B) or the following polymer (B) and polymer (B '). (Here, polymer (A) does not include polymer (B)) Polymer (A): a polyamic acid (A) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid containing, as the structural unit derived from the tetracarboxylic acid derivative, a structural unit (a-1Ta) represented by formula (1Ta) and containing, as the structural unit derived from the diamine, a structural unit (a-1Da) represented by formula (1Da). Polymer (B): a polyamic acid (B) having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid containing, as the structural unit derived from the tetracarboxylic acid derivative, a structural unit (b-1Tb) represented by formula (1Tb), and containing, as the structural unit derived from the diamine, a structural unit (b-1Db) represented by formula (1Db). At least a part of the terminal of the polyamic acid (B) contains a non-amino group, the non-amino group is a functional group represented by structural formula (E), and the presence rate of the terminal amino group in the polyamic acid (B) is 60% or less based on the total terminal of the polyamic acid (B). Polymer (B '): a polyamic acid (B') having a structural unit derived from a tetracarboxylic acid derivative and a structural unit derived from a diamine, the polyamic acid containing a structural unit (b-1Tb) represented by formula (1Tb) as the structural unit derived from the tetracarboxylic acid derivative and not containing a structural unit (a-1Da) represented by formula (1Ta), and the polyamic acid containing a structural unit (b-1Da) represented by formula (1Ta) as the structural unit derived from the diamine as the structural unit derived from the diamine. The polyamic acid (B) contains a structural unit (b-1Db) represented by formula (1Db) or a structural unit (b-1Db ') represented by formula (1Db'), and the content of terminal amino groups in the polyamic acid (B ') is greater than 60% based on the total terminals of the polyamic acid (B). (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) (Definition of each symbol is as defined in the specification) .
Owner:NISSAN CHEM CORP

Sustained-release pharmaceutical preparation of fused tricyclic gamma-amino acid derivative and preparation method of sustained-release pharmaceutical preparation

The invention relates to a sustained-release pharmaceutical preparation of a fused tricyclic gamma-amino acid derivative and a preparation method of the sustained-release pharmaceutical preparation. The fused tricyclic gamma-amino acid derivative is a compound as shown in a formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof.
Owner:SICHUAN HAISCO PHARMA CO LTD

Stereospecific cyanation reaction using copper catalyst

To provide a method for synthesizing a cyanide that is a precursor to a β-amino acid derivative having bulky optical activity, intended for peptide synthesis including a β-amino acid having bulky optical activity.SOLUTION: The present invention provides a method for synthesizing a cyanation product having a bulky tertiary alkylated structure and having optical activity, by reacting an α-haloamide having a bulky tertiary alkylated structure and having optical activity with a cyanohydrin in the presence of a copper catalyst.SELECTED DRAWING: None
Owner:IWATANI CORP +1

Composition and method for prolonging shelf life of liquid MDI product

The invention discloses a composition and a method for prolonging the shelf life of a liquid MDI product. The composition comprises (a) diphenylmethane diisocyanate (MDI), (b) at least one organophosphoric acid derivative with a structure shown in a formula (I), and (c) at least one metal carbonyl compound with a structure shown in a formula (II). The method provided by the invention can inhibit the formation of the MDI dimer, and especially prominently, can improve the solubility of the MDI dimer in a liquid MDI product, reduce the freezing point of the liquid MDI product, prolong the storage life of the liquid MDI product, and improve the storage and transportation stability and operation convenience of the liquid MDI product.
Owner:WANHUA CHEM GRP CO LTD

Amino acid derivative carrier, preparation method and application thereof

The invention relates to an amino acid derivative carrier as well as a preparation method and application thereof, and belongs to the technical field of biology, and the preparation method of the amino acid derivative carrier comprises the following steps: providing a cationic amino acid monomer and a neutral-polyanion block polymer template; a cationic amino acid monomer, a neutral-polyanion block polymer template, a cross-linking agent and a photoinitiator are mixed and react under the irradiation of ultraviolet light to obtain an amino acid derivative carrier, and the amino acid derivative carrier is cationic nanogel. The amino acid derivative carrier prepared by the preparation method disclosed by the invention can be used as a nucleic acid drug delivery carrier, and has the advantages of strong nucleic acid loading capacity, high transfection efficiency, safety and the like.
Owner:SHANGHAI HULIJIA IND